Literature DB >> 14520421

Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.

P Martin1, N Bleyzac, G Souillet, C Galambrun, Y Bertrand, P H Maire, R W Jelliffe, G Aulagner.   

Abstract

In order to determine optimal CsA trough blood concentrations (TBC) in the early post transplantation period, we analysed relationships between TBC and acute graft-versus-host disease (aGVHD) in paediatric SCT. A total of 94 children consecutively underwent allogeneic stem cell transplantation (SCT) from: matched-sibling (MSD) (n=36), mismatched-related (MMRD) (n=3) and unrelated donors (UD) (n=55). GVHD prophylaxis usually included CsA alone or with methotrexate. Antithymocyte globulin was added in UD-SCT. TBC during the first weeks of post transplantation were estimated retrospectively by a Bayesian pharmacokinetic method and statistically associated with aGVHD. In MSD-SCT, the mean TBC during the first 2 weeks post transplantation were 42+/-10 and 90+/-7 ng/ml, respectively, in patients with grade II-IV and 0-I aGVHD (P=0.001). In SCT from UD and MMRD, TBC were 73+/-4 vs 95+/-8 ng/ml (P=0.284). For TBC >85 ng/ml, no patient developed grade II-IV aGVHD, 10 developed mild aGVHD and 30 had no aGVHD. For TBC <65 ng/ml, 7/11 patients receiving an MSD-SCT and 4/18 receiving an UD- or MMRD-SCT developed grade II-IV aGVHD. The mean TBC corresponding to each grade were: no GVHD: 101+/-10 ng/ml, mild: 77+/-11 ng/ml, moderate: 61+/-13 ng/ml, severe: 56+/-15 ng/ml (P <0.001). These results reveal a strong relationship between TBC during the early post transplantation period and the severity of aGVHD in paediatric SCT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14520421     DOI: 10.1038/sj.bmt.1704213

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  13 in total

1.  Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients.

Authors:  Isabel Sánchez-Ortega; Lourdes Vázquez; Carmen Montes; Beatriz Patiño; Montserrat Arnan; Arancha Bermúdez; Lucrecia Yáñez; Teresa Caballero; Rafael F Duarte
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

2.  Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

3.  Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Authors:  Ran Reshef; Alex Ganetsky; Edward P Acosta; Robin Blauser; Lisa Crisalli; Jessica McGraw; Noelle V Frey; Elizabeth O Hexner; James A Hoxie; Alison W Loren; Selina M Luger; James Mangan; Edward A Stadtmauer; Rosemarie Mick; Robert H Vonderheide; David L Porter
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-10       Impact factor: 5.742

Review 4.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.

Authors:  Ron Ram; Barry Storer; Marco Mielcarek; Brenda M Sandmaier; David G Maloney; Paul J Martin; Mary E D Flowers; Bee K Chua; Marcello Rotta; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-26       Impact factor: 5.742

6.  Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-10-21       Impact factor: 4.200

7.  Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.

Authors:  Céline Dartois; Gilles Freyer; Mauricette Michallet; Emilie Hénin; Benoît You; Isabelle Darlavoix; Claudine Vermot-Desroches; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.

Authors:  N Bleyzac; D Cuzzubbo; C Rénard; N Garnier; V Dubois; C Domenech; M-P Goutagny; A Plesa; N Grardel; S Goutelle; A Janoly-Duménil; Y Bertrand
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

9.  Assessment of cyclosporine serum concentrations on the incidence of acute graft versus host disease post hematopoietic stem cell transplantation.

Authors:  Sara Zeighami; Molouk Hadjibabaie; Asieh Ashouri; Amir Sarayani; Seyed Hamid Khoee; Sarah Mousavi; Mania Radfar; Ardeshir Ghavamzadeh
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

10.  Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.

Authors:  Irene García Cadenas; David Valcarcel; Rodrigo Martino; J L Piñana; Pere Barba; Silvana Novelli; Albert Esquirol; Ana Garrido; Silvana Saavedra; Miquel Granell; Carol Moreno; Javier Briones; Salut Brunet; Jorge Sierra
Journal:  Mediators Inflamm       Date:  2014-01-30       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.